Form 4: SERA CMO Granted 75,000 RSUs and 107,000 Stock Options

SERA PROGNOSTICS' Chief Medical Officer, Tiffany Eul Davis Inglis, was granted 75,000 restricted stock units and 107,000 stock options, effective October 15, 2025.

Summary

• Tiffany Eul Davis Inglis, Chief Medical Officer of SERA PROGNOSTICS, INC., acquired 75,000 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs).
• The RSUs were granted at a price of $0 per share and are directly beneficially owned.
• These RSUs vest over four years: 25% on the first anniversary of the vesting commencement date (October 10, 2025), and 1/12 of the remaining amount vests quarterly for three years thereafter, contingent on continued service.
• Additionally, Ms. Inglis acquired 107,000 stock options to buy Class A Common Stock.
• The stock options have an exercise price of $3.13 per share and were granted at a price of $0.
• These stock options vest over four years: 25% on the first anniversary of the vesting commencement date (October 10, 2025), and 1/36 of the remaining amount vests monthly for three years thereafter, contingent on continued service.
• The stock options expire on October 15, 2035.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation grant to a key executive, which is generally viewed as a neutral to slightly positive event as it aligns management incentives with shareholder interests, without providing new fundamental performance data.

Positives

• The equity grants align the Chief Medical Officer's long-term interests with those of shareholders, incentivizing sustained performance and company growth.
• The vesting schedules for both RSUs and stock options encourage retention of key management personnel over a four-year period.

Negatives

• The issuance of new equity (RSUs and underlying shares for options) could lead to minor dilution for existing shareholders upon vesting and exercise.

Risks

• The value of the granted RSUs and stock options is subject to the future market price fluctuations of SERA PROGNOSTICS' Class A Common Stock.
• The vesting of both RSUs and stock options is contingent upon the reporting person continuing to provide services to the issuer, meaning forfeiture could occur if employment ceases before vesting is complete.

Future Outlook

The equity grants, with their multi-year vesting schedules, indicate an expectation of continued service from the Chief Medical Officer and a long-term commitment to the company's strategic objectives.

Industry Context

Equity compensation, including RSUs and stock options, is a standard practice in the biotechnology and healthcare sectors to attract, retain, and incentivize key executives, aligning their financial success with the company's performance and shareholder value creation.

Comparison to Industry Standards

• The structure of these equity grants, including the mix of RSUs and stock options and their multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotechnology and pharmaceutical industries.
• The use of a Rule 10b5-1 plan for these transactions is a common corporate governance practice to allow insiders to trade company stock without concerns of insider trading, demonstrating adherence to regulatory best practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution from the vesting and exercise of RSUs and stock options, but also benefit from increased alignment of executive interests with long-term company performance.
• Employees: The grant to a key executive may signal stability and confidence in the company's leadership and future direction.

Next Steps

• The Chief Medical Officer must continue to provide services to the issuer for the RSUs and stock options to vest according to their respective schedules, commencing October 10, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive, which is a standard practice for incentivizing management. It does not contain new fundamental information about the company's financial performance, strategic direction, or operational results that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not alter the investment thesis.

Keywords

SERA PROGNOSTICS, SERA, Tiffany Eul Davis Inglis, Chief Medical Officer, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Insider Transaction, Form 4, 10b5-1 Plan, Executive Compensation